EPISODE · Sep 11, 2018 · 21 MIN
Purdue Pharma's 'one-two' punch
from Behind the Money
The name “Sackler” adorns museums and art galleries around the world. But the family name has also become tainted by its association with the US opioid crisis, amid accusations that OxyContin, more than any other drug, is responsible for sparking one of the worst public health epidemics of modern times. The FT's David Crow explains how the Sackler family company Purdue Pharma got its hold on the opioid market. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
The name “Sackler” adorns museums and art galleries around the world. But the family name has also become tainted by its association with the US opioid crisis, amid accusations that OxyContin, more than any other drug, is responsible for sparking one of the worst public health epidemics of modern times. The FT's David Crow explains how the Sackler family company Purdue Pharma got its hold on the opioid market. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Purdue Pharma's 'one-two' punch
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.